Cargando…

1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic

BACKGROUND: Omadacycline (OMC) is a novel aminomethylcycline with activity against Gram-positive, many Gram-negative, anaerobic, and atypical pathogens. It is in clinical development as once-daily oral (PO) and intravenous (IV) monotherapy for acute bacterial skin and skin structure infections (ABSS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Opal, Steven, File, Thomas M, Van Der Poll, Tom, McGovern, Paul, Tzanis, Evan, Chitra, Surya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252771/ http://dx.doi.org/10.1093/ofid/ofy210.1205

Ejemplares similares

An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2019)

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
por: Bundrant, Lu Ann, et al.
Publicado: (2018)

Omadacycline: a novel aminomethylcycline
por: Burgos, Rodrigo M, et al.
Publicado: (2019)

Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline
por: Honeyman, Laura, et al.
Publicado: (2015)

1356. Improvement in Quality of Life for Adults With Acute Bacterial Skin and Skin Structure Infections Following Treatment With Omadacycline or Linezolid
por: Tzanis, Evan, et al.
Publicado: (2018)

The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study
por: Hunt, Thomas L., et al.
Publicado: (2020)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

Efficacy and Safety of Omadacycline Versus Linezolid in Acute Bacterial Skin and Skin Structure Infections in Persons Who Inject Drugs
por: Moran, Gregory J., et al.
Publicado: (2022)

The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome
por: Heidrich, Corina G., et al.
Publicado: (2016)

700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
por: Pai, Manjunath P, et al.
Publicado: (2019)

Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections
por: Pai, Manjunath P, et al.
Publicado: (2021)

Omadacycline for Acute Bacterial Skin and Skin Structure Infections
por: Abrahamian, Fredrick M, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
por: Overcash, J. Scott, et al.
Publicado: (2019)

1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
por: Abrahamian, Fredrick M, et al.
Publicado: (2018)

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
por: Trang, M., et al.
Publicado: (2023)

734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
por: Friedrich, Lawrence, et al.
Publicado: (2019)

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
por: Lakota, Elizabeth A, et al.
Publicado: (2019)

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
por: Gotfried, Mark H., et al.
Publicado: (2017)

Effect of Food on the Bioavailability of Omadacycline in Healthy Participants
por: Tzanis, Evan, et al.
Publicado: (2016)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

1688. Omadacycline in Female Adults With Cystitis: Results From a Randomized, Double-Blinded, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models
por: Tan, Xiaojuan, et al.
Publicado: (2020)

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia
por: Trang, M., et al.
Publicado: (2022)

Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2021)

110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2019)

733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

P1374: RAMAN SPECTROSCOPY STUDIES OF IMMUNE RESPONSE ELEMENTS
por: Laskowska, Paulina, et al.
Publicado: (2023)

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis
por: Karau, Melissa J., et al.
Publicado: (2022)

Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice
por: Ramirez, Julio A, et al.
Publicado: (2019)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

1374. Clinical Outcomes of Sepsis According to Race at University of Minnesota Medical Center
por: Meyer-Mueller, Cameron, et al.
Publicado: (2021)

First operation of the new I5 PU's: Run 422 - 1.3.74
por: Borer, J, et al.
Publicado: (1974)

CGH analysis in Colombian patients: findings of 1374 arrays in a seven-year study
por: García-Acero, Mary, et al.
Publicado: (2018)

1374. Foodborne disease outbreak at a delivery pizza and sushi restaurant, Kazakhstan, 2023
por: Ablimitova, Feruza, et al.
Publicado: (2023)

661. In vitro Activity of Omadacycline and Comparator Antibiotics against Clostridioides difficile
por: Skinner, Andrew M, et al.
Publicado: (2022)

Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial
por: Rodriguez, George D., et al.
Publicado: (2023)

Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection
por: Nicklas, Danielle A., et al.
Publicado: (2022)

1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
por: Rodriguez, Mauricio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uhr0smgmbq8hp9fti75judupe4